b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">28641354</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>07</Month>\n            <Day>11</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>07</Month>\n            <Day>11</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1438-9592</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>142</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2017</Year>\n                        <Month>Jun</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Zentralblatt fur Chirurgie</Title>\n                <ISOAbbreviation>Zentralbl Chir</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>[Acute Liver Failure, Acute-On-Chronic Liver Failure, Hepatorenal Syndrome, Hepatopulmonary Syndrome and Portopulmonary Hypertension, Artificial Liver Support on the ICU].</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>275-286</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0043-106198</ELocationID>\n            <Abstract>\n                <AbstractText><b>Background</b> Acute hepatic dysfunction in the form of acute liver failure (ALF) or acute-on-chronic liver failure (ACLF) is a disease with a high risk of mortality and requires interdisciplinary intensive care. <b>Aim</b> This article explains the nomenclature, pathophysiology, prognosis and possible treatment options of ALF and ACLF, including the possibilities of extracorporeal liver support therapy at the point of liver transplantation (LTx). <b>Method</b> Narrative review with a selective literature review and representative case studies. <b>Results/Corner Points</b> ALF and ACLF may have several causes and are associated with high mortality. The causes of ALF must be accurately diagnosed because targeted treatment options are available. Both ALF and ACLF may require a liver transplantation for the patient\'s survival. For ALF and ACLF there are different criteria for decision-making on liver transplantation and graft allocation. For extracorporeal liver support therapy, two methods have been established (MARS [molecuar adsorbent recirculating system] and FPSA [fractionated plasma separation and adsorption] Prometheus<sup>\xc2\xae</sup>). Both approaches may have the potential to increase the probability of survival of patients with ALF or ACLF. In some cases they can be used for bridging to liver transplantation, in individual cases also for primary poison elimination, e.g. after Amatoxin ingestion. Both methods are not suitable for long-term therapy. <b>Conclusion</b> Acute liver failure (ALF) and acute on chronic liver failure (ACLF) are serious diseases with a high risk of mortality. Affected patients should receive immediate interdisciplinary intensive care in a (tertiary) centre with the aim to clarify the cause of the disease as well as possible treatment options with respect to available extracorporeal liver support therapy and liver transplantation.</AbstractText>\n                <CopyrightInformation>Georg Thieme Verlag KG Stuttgart \xc2\xb7 New York.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Lodes</LastName>\n                    <ForeName>Uwe</ForeName>\n                    <Initials>U</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Klinik f\xc3\xbcr Allgemein-, Viszeral- und Gef\xc3\xa4\xc3\x9fchirurgie, Universit\xc3\xa4tsklinikum Magdeburg A.\xe2\x80\x8a\xc3\xb6.\xe2\x80\x8aR., Deutschland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jacob</LastName>\n                    <ForeName>David</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Klinik f\xc3\xbcr Allgemein-, Viszeral- und Gef\xc3\xa4\xc3\x9fchirurgie, Universit\xc3\xa4tsklinikum Magdeburg A.\xe2\x80\x8a\xc3\xb6.\xe2\x80\x8aR., Deutschland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Meyer</LastName>\n                    <ForeName>Frank</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Klinik f\xc3\xbcr Allgemein-, Viszeral- und Gef\xc3\xa4\xc3\x9fchirurgie, Universit\xc3\xa4tsklinikum Magdeburg A.\xe2\x80\x8a\xc3\xb6.\xe2\x80\x8aR., Deutschland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>ger</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <VernacularTitle>Akutes Leberversagen, akut-auf-chronisches Leberversagen, hepatorenales Syndrom, hepatopulmonales Syndrom und portopulmonale Hypertonie, Leberunterst\xc3\xbctzungsverfahren auf der Intensivstation.</VernacularTitle>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>06</Month>\n                <Day>22</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Germany</Country>\n            <MedlineTA>Zentralbl Chir</MedlineTA>\n            <NlmUniqueID>0413645</NlmUniqueID>\n            <ISSNLinking>0044-409X</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D065290" MajorTopicYN="N">Acute-On-Chronic Liver Failure</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020065" MajorTopicYN="N">Hepatopulmonary Syndrome</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006530" MajorTopicYN="N">Hepatorenal Syndrome</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006975" MajorTopicYN="N">Hypertension, Portal</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName>\n                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D033183" MajorTopicYN="N">Interdisciplinary Communication</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017114" MajorTopicYN="N">Liver Failure, Acute</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019164" MajorTopicYN="Y">Liver, Artificial</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <OtherAbstract Type="Publisher" Language="ger">\n            <AbstractText><b>Hintergrund</b> Die akute Leberfunktionsst\xc3\xb6rung als akutes Leberversagen (ALV) oder akut-auf-chronisches Leberversagen (ACLV) ist ein intensivmedizinisches, interdisziplin\xc3\xa4r zu behandelndes Krankheitsbild mit einem hohen Letalit\xc3\xa4tsrisiko. <b>Ziel</b> Nomenklatur, Pathophysiologie, Prognose und m\xc3\xb6gliche Therapieoptionen des ALV und des ACLV sollen erl\xc3\xa4utert werden einschlie\xc3\x9flich der M\xc3\xb6glichkeiten der extrakorporalen Leberersatztherapie an der Schwelle zur Lebertransplantation (LTx). <b>Methode</b> Narrative \xc3\x9cbersicht mit selektiver Literaturrecherche und eigenen repr\xc3\xa4sentativen Fallbeispielen. <b>Ergebnisse/Eckpunkte</b> ALV und ACLV haben vielf\xc3\xa4ltige Ursachen und eine hohe Letalit\xc3\xa4t. Beim ALV kommt es auf die genaue Ermittlung der Ursache an, weil teilweise spezielle Therapiem\xc3\xb6glichkeiten zur Verf\xc3\xbcgung stehen. Sowohl bei ALV und ACLV kann zum \xc3\x9cberleben eine Lebertransplantation erforderlich sein, f\xc3\xbcr ALV und ACLV existieren unterschiedliche Kriterien f\xc3\xbcr Indikationsstellung und Transplantatallokation. Zur extrakorporalen Leberunterst\xc3\xbctzung haben sich 2 Verfahren etabliert (MARS [molecuar adsorbent recirculating system] und FPSA [fractionated plasma separation and adsorption] Prometheus<sup>\xc2\xae</sup>). Beide Verfahren k\xc3\xb6nnen in der Lage sein, bei einem ALV oder einem ACLV die \xc3\x9cberlebenswahrscheinlichkeit zu erh\xc3\xb6hen, und sie werden in einzelnen F\xc3\xa4llen zum Bridging zur LTx eingesetzt, au\xc3\x9ferdem in Einzelf\xc3\xa4llen zur prim\xc3\xa4ren Giftelimination, z.\xe2\x80\x8aB. nach Amatoxiningestion. Beide Verfahren sind nicht als Dauertherapie geeignet. <b>Schlussfolgerung</b> Akutes Leberversagen und akut-auf-chronisches Leberversagen sind schwerwiegende Krankheitsbilder mit hohem Letalit\xc3\xa4tsrisiko. Betroffene Patienten sollten schnellstm\xc3\xb6glich einer interdisziplin\xc3\xa4ren Intensivtherapie in einem (terti\xc3\xa4ren) Zentrum zugef\xc3\xbchrt werden mit dem Ziel, die Krankheitsursache und m\xc3\xb6gliche Therapieoptionen hinsichtlich vorgehaltener extrakorporaler Leberunterst\xc3\xbctzungsverfahren und Lebertransplantation abzukl\xc3\xa4ren.</AbstractText>\n        </OtherAbstract>\n        <CoiStatement>Interessenkonflikt: Nein.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>6</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>6</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>7</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">28641354</ArticleId>\n            <ArticleId IdType="doi">10.1055/s-0043-106198</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'